Zura Bio Limited (NASDAQ:ZURA) EVP Buys $10,000.35 in Stock

Zura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala acquired 3,195 shares of Zura Bio stock in a transaction dated Monday, April 22nd. The stock was acquired at an average cost of $3.13 per share, with a total value of $10,000.35. Following the completion of the transaction, the executive vice president now directly owns 3,195 shares of the company’s stock, valued at approximately $10,000.35. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zura Bio Stock Down 4.9 %

ZURA stock traded down $0.17 during midday trading on Wednesday, hitting $3.31. The stock had a trading volume of 826,726 shares, compared to its average volume of 278,140. Zura Bio Limited has a 52 week low of $2.00 and a 52 week high of $14.00. The stock has a 50-day simple moving average of $3.21 and a 200 day simple moving average of $4.04.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ZURA. Raymond James & Associates lifted its position in Zura Bio by 14.0% in the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after purchasing an additional 9,481 shares during the period. Bank of New York Mellon Corp acquired a new position in Zura Bio during the third quarter worth $224,000. Forefront Analytics LLC acquired a new position in Zura Bio during the third quarter worth $95,000. Silverarc Capital Management LLC raised its stake in Zura Bio by 152.5% during the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after acquiring an additional 244,040 shares in the last quarter. Finally, Eisler Capital US LLC acquired a new position in Zura Bio during the third quarter worth $660,000. 61.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Oppenheimer reissued an “outperform” rating and issued a $16.00 price objective (down from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $16.40.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.